Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
Niels Brandt, Marie Louise Johansen, Jon Rasmussen, Julie Lyng Forman, Maria Refsgaard Holm, Jens Faber, Patrick Rossignol, Morten Schou, Caroline Kistorp
Topics & Concepts
EplerenoneMedicineInternal medicineRenal functionMineralocorticoid receptorPlaceboBlood pressureType 2 diabetesUrologyEndocrinologyKidney diseaseAmbulatory blood pressureCreatinineDiabetes mellitusGastroenterologyAldosteronePathologyAlternative medicineHormonal Regulation and HypertensionAdrenal Hormones and DisordersBlood Pressure and Hypertension Studies